Futura Medical PLC (FUM)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
1.215p
Buy
1.30p
-0.062p (-4.77%)
Prices updated at 18 Dec 2025, 09:43 GMT
| Prices minimum 15 mins delay
Prices in GBX
Futura Medical PLC is a UK based drug manufacturer. Its business is to manufacture pharmaceutical products mainly for the treatment of erectile dysfunction and a measure against pain relief.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
-
CEO
Mr. Alexander James Hanbury Duggan
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
17
Head office
40 Occam Road
Guildford
United Kingdom
GU2 7YG
Key personnel
Owner name | Salary |
|---|---|
Mr. Andrew Vaughan Unitt Non-Executive Director, Senior Independent Director | - |
Mr. Gordon Roy Davis Non-Executive Director | - |
Mr. Kenneth William James Executive Director, Head of RandD | - |
Ms. Angela Hildreth Executive Director, Finance Director, Chief Operating Officer and Company Secretary | - |
Mr. Alexander James Hanbury Duggan Executive Director, Chief Executive Officer (Interim) | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Unicorn Asset Management Ltd | 5,750,000 |
| Unicorn AIM VCT Series 3 ORD | 5,750,000 |
| March Asset Management SGIIC | 410 |
| Chelverton Asset Management Ltd | - |
| MI Chelverton UK Equity Growth Fund | - |
Director dealings
Date | Action |
|---|---|
| 04 Dec 2025 | Purchase |
| 04 Dec 2025 | Purchase |
| 04 Dec 2025 | Purchase |
| 13 Nov 2025 | Sale |
| 16 Jan 2025 | Purchase |
| 16 Jan 2025 | Purchase |
| 16 Jan 2025 | Purchase |
| 16 Jan 2025 | Purchase |
| 16 Jan 2025 | Purchase |
| 16 Jan 2025 | Purchase |
| 16 Jan 2025 | Purchase |
| 16 Jan 2025 | Purchase |
| 16 Jan 2025 | Purchase |
Please note that past performance is not a reliable indicator of future returns.